MARKET

CANF

CANF

Can Fite Biophar
AMEX
2.465
+0.085
+3.57%
Closed 15:58 05/20 EDT
OPEN
2.380
PREV CLOSE
2.380
HIGH
2.500
LOW
2.330
VOLUME
44.45K
TURNOVER
0
52 WEEK HIGH
3.330
52 WEEK LOW
1.810
MARKET CAP
12.30M
P/E (TTM)
-1.3759
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CANF last week (0513-0517)?
Weekly Report · 21h ago
Can-Fite Rallies Oncologists for Liver Cancer Study
TipRanks · 05/13 11:57
Weekly Report: what happened at CANF last week (0506-0510)?
Weekly Report · 05/13 09:35
Can-Fite Biopharma Price Target Maintained With a $18.00/Share by HC Wainwright & Co.
Dow Jones · 05/09 17:57
HC Wainwright & Co. Reiterates Buy on Can Fite Biofarma, Maintains $18 Price Target
Benzinga · 05/09 17:47
Buy Rating Affirmed for Can-Fite BioPharma on IND Clearance and Positive Clinical Study Outlook
TipRanks · 05/09 14:45
Can-Fite stock up on FDA IND clearance for namodenoson to treat MASH patients in mid-stage study
Can-Fite stock up on FDA IND clearance for namodenoson to treat MASH patients in mid-stage study. FDA granted clearance for the treatment of patients with metabolic dysfunction-associated steatohepatitis for the company's ongoing Phase IIb clinical study.
Seeking Alpha · 05/09 13:08
Can-Fite Advances MASH Treatment into Phase IIb
TipRanks · 05/09 11:58
More
About CANF
Can Fite Biofarma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. It's technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.

Webull offers Can Fite Biopharma Ltd stock information, including AMEX: CANF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CANF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CANF stock methods without spending real money on the virtual paper trading platform.